Comments
Regeneron says eye drug capturing Roche patients
14.03.2012. | (Reuters) - Regeneron Pharmaceuticals Inc said surveys suggest its Eylea treatment for macular degeneration is capturing 60 percent of its sales from patients that have abandoned Roche Holding AG's Lucentis and Avastin medicines....
